AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00900809 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Neukoplast™ (NK-92)
Description: The Neukoplast™ (NK-92) cells will be administered intravenously over 60 minutes. The starting dose of Neukoplast™ (NK-92) cells will be 1 x 10e9 ZRx-101 cells/m2 (The 3 dose levels are: 1 x 10e9 cells/m2, 3 x 10e9 cells/m2 and 5 x 10e9 cells/m2). The second infusion will only be administered after 24 hours if no unacceptable or dose limiting toxicities side effects due to the infusion of Neukoplast™ were encountered after the first infusion.
Study NCT03311009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG1972 cohort 1
Description: GLPG1972 dose 1 provided as oral tablets q.d.
Study NCT03311009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG1972 cohort 2
Description: GLPG1972 dose 2 provided as oral tablets q.d.
Study NCT03311009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG1972 cohort 3
Description: GLPG1972 dose 3 provided as oral tablets q.d.
Study NCT03311009 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo provided as oral tablets q.d.
Study NCT02387814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered Orally
Study NCT04503798 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Goal Management Training
Description: Pre-recorded videos and games combine psycho-education, targeted skills training, and mindfulness practice to teach a system where participants can take control of their attention and cognitive faculties.
Study NCT02002156 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG, NeisVac-C®, Pediacel®, Infanrix™, Prevenar-13®, Menitorix®, Priorix®, Rotarix®
Description: This group will receive BCG at birth and all routine vaccinations.
Study NCT02002156 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG, NeisVac-C®, Pediacel®, Infanrix™, Prevenar-13®, Menitorix®, Priorix®, Rotarix®
Description: This group will receive BCG at three months old and all routine vaccinations.
Study NCT02002156 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NeisVac-C®, Pediacel®, Infanrix™, Prevenar-13®, Menitorix®, Priorix®, Rotarix®
Description: This group will receive no BCG but will receive all routine vaccinations.
Study NCT00833781 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: mRNA-transfected autologous dendritic cells
Description: Injections will be administered intradermally at weeks 0, 2, 6 and 10.
Study NCT00833781 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: autologous dendritic cells with no mRNA transfection
Description: Injections will be administered intradermally at weeks 0, 2, 6 and 10.
Study NCT05464732 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vivity IOL
Description: The Vivity IOL will be implanted bilaterally in all subjects.
Study NCT05464732 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vivity IOL
Description: The Vivity IOL will be implanted bilaterally in all subjects.
Study NCT02307474 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: 3 fractions of 16 Gy per fraction to a total dose of 48 Gy on non-consecutive day within a 10 day time span
Study NCT02307474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib Hydrochloride
Description: Given PO starting at 800mg to be systematically altered following drug related toxicities.
Study NCT01847313 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: Daily administration of liraglutide for 6 months
Study NCT02459613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 99mTc-Annexin V-128 SPECT
Study NCT00229541 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Counselling and 3-week medical in-patient rehabilitation
Description: Counselling and 3-week medical in-patient rehabilitation in IG
Study NCT03253978 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotatic Radiotherapy
Description: SABR to prostate / seminal nodes
Study NCT03253978 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotatic Radiotherapy
Description: SABR to prostate / seminal nodes
Study NCT04034030 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: Each patient will receive a 10 minute treatment of one time stimulation of the Epileptogenic Cortical Area (ECA). The TRPMS cap will be worn over the previously fixed scalp EEG electrodes. The procedure during this treatment session will consist of positioning a device microstimulator component centered on an area of focal epileptiform discharges (identified with EEG electrode placement) with the patient relaxing in a chair.~The stimulus parameters used will be 120 stimulus trains of 100 ms in duration, each train delivered every 5 s for total session duration of 10 min. . The investigators will measure the subject for adequate placement of the device prior to stimulation. Once the placement of the device is confirmed, the study technician administrating the treatment will turn on the device using the app downloaded on an electronic device connected by Bluetooth to the device.
Study NCT03863275 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: functional apparatus
Description: The EMG activity will be recorded during different shots: T0. The activity of the muscles of the mastication in the position of clinical rest for a minute, in maximum intercuspidation. (It will be measured with a dynamometer to standardize the force), and with the use of the equipment. T1 The patient's citation is scheduled six months after the use of myofunctional device Sn1 and the test will be performed again measuring electrical activity of right and left masseter and right and left temporal muscle at clinical rest for one minute, in maximum intercuspation, and with the use of the equipment To avoid the effects of fatigue, a rest period of at least 5 minutes between each of the recordings will be allowed
Study NCT03863275 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Diagnosis and observation
Description: Six months of observation in the control group: patients group the efforts are controlled. to obtain models and have an observation of the molar classification, and to verify if the terms of the inclusion in the study are taken into account, once it is confirmed that the activity is observed in the muscular activity of the chewing muscles, in two stages , at the beginning of the session and six months later. .
Study NCT00877682 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryoablation
Description: Under general anesthetic using ultrasonic guidance, freezing (cryoablation) portion of prostate.
Study NCT00563303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydrocortisone
Description: 200mg/jour (solution of 48mL), Day 1 to Day 4 100mg/jour (solution of 48mL), Day 5 50mg/jour (solution of 48mL), Day 6
Study NCT00563303 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl
Description: 48mL from Day 1 to Day 6
Study NCT03323632 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MyndMove
Description: During a MyndMove therapy session, the patient is instructed to attempt to execute a task voluntarily. As the patient is attempting to perform the designated task, specific muscles in the arm are stimulated to generate contractions that produce the desired movement. After a brief interval of the patient attempting to initiate a movement the therapist activates the MyndMove stimulation protocol, which generates bursts of short electrical pulses, using surface electrodes, to produce muscle contractions enabling the patient to complete the desired/instructed task. Proper sequencing of the muscle contractions as per the MyndMove protocols are tailored to achieve a wide range of reaching and grasping functions. The technique stimulates non-damaged pathways of the central nervous system.
Study NCT00864942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bendamustine and lenalidomide
Description: Lenalidomide is given daily orally for one week followed by bendamustine HCL 90 mg/m2 IV over 30 to 60 minutes on days 1 and 2 in combination with lenalidomide, given orally, in dose-escalating cohorts. After a maximum of 6 cycles of combination therapy with bendamustine and lenalidomide, lenalidomide monotherapy is continued for an additional 6 cycles as tolerated or until disease progression.
Study NCT00864942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-NHL
Description: Bendamustine HCL 90 mg/m2 given intravenously over 30 to 60 minutes on days 1 and 2 in combination with lenalidomide, given orally, in dose-escalating cohorts. After a maximum of 6 cycles of combination therapy with bendamustine and lenalidomide, lenalidomide monotherapy is continued for an additional 6 cycles as tolerated or until disease progression.
Study NCT00864942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLR-CLL
Description: Lenalidomide is given orally for 7 days followed by rituximab 375 mg/m2 on day 1 in addition to bendamustine 90 mg/m2 intravenously over 30-60 minutes on days 1 and 2 and lenalidomide orally daily every 28 days for a total of 6 cycles. After 6 cycles of bendamustine, lenalidomide and rituximab, lenalidomide monotherapy is administered as continued therapy for an additional 6 cycles as tolerated or until disease progression.
Study NCT00864942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLR-NHL
Description: Rituximab 375 mg/m2 is given on day 1 on day 1 in addition to bendamustine 90 mg/m2 intravenously over 30-60 minutes on days 1 and 2 and lenalidomide orally daily every 28 days for a total of 6 cycles. After 6 cycles of bendamustine, lenalidomide and rituximab, lenalidomide monotherapy is administered as continued therapy for an additional 6 cycles as tolerated or until disease progression.
Study NCT03803722 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eyestil Protection® unidose
Description: to demonstrate the non-inferiority of Eyestil Protection® in terms of performance and safety, when compared to Vismed® in treatment of dry eye disease.
Study NCT01301131 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: 80 ml of fermented dairy product containing L. casei shirota via nasogastric tube once daily and 80 ml of fermented dairy product containing L. casei shirota oral rinse once daily
Study NCT01301131 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: control
Description: usual oral care
Study NCT01040013 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopy
Description: Laparoscopic Left-Colectomy
Study NCT01040013 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: left colectomy by laparotomy
Description: PatientS will be operated by laparotomy
Study NCT02609737 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/CT Imaging
Study NCT02609737 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 68Ga-DOTA-JR11
Study NCT02609737 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 177Lu-DOTA-JR11
Study NCT01806597 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: secukinumab 150 mg
Description: Study treatment were provided in pre-filled syringes of secukinumab 150 mg in 1 mL. Each dosing consiseds of one secukinumab 150 mg s.c. injection plus one placebo secukinumab s.c. injection and took place once weekly during five weeks (at Baseline, Weeks 1, 2, 3 and 4), then once every four weeks starting at Week 8 until Week 128 inclusive. In order to maintain the blinding, patients also received two placebo injections at Weeks 17, 18 and 19. Patients self-administered study treatment under the supervision of site personnel when injections occur during study visits, or at home otherwise.
Study NCT01806597 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: secukinumab 300 mg
Description: Study treatment were provided in pre-filled syringes of secukinumab 150 mg in 1 mL. Each dosing consisted of two secukinumab 150 mg s.c. injections and took ke place once weekly during five weeks (at Baseline, Weeks 1, 2, 3 and 4), then once every four weeks starting at Week 8 until Week 128 inclusive. In order to maintain the blinding, patients also receives two placebo injections at Weeks 17, 18 and 19. Patients self-administered study treatment under the supervision of site personnel when injections occur during study visits, or at home otherwise.
Study NCT01806597 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo were provided in 1 mL pre-filled syringes. Each dosing consisted of two s.c. injections and took place once weekly during five weeks (at Baseline, Weeks 1, 2, 3 and 4), then at Week 8 and at Week 12. At Week 16, ppIGA responders continued on placebo with dosing at Weeks 16, 17, 18, 19 and 20, then once every four weeks from Week 24 until Week 76 inclusive. At Week 80, ppIGA responders ended their participation in the study while ppIGA non-responders were re-randomized, to receive 150 mg or 300 mg secukinumab once every four weeks starting at Week 80 until Week 128 inclusive. Patients self-administered study treatment under the supervision of site personnel when injections occur during study visits, or at home otherwise.
Study NCT02958540 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SynGEM
Description: Prime / boost vaccination in each group
Study NCT02958540 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: prime /boost vaccination
Study NCT01017029 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus
Study NCT01017029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil + Everolimus
Study NCT00139386 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Candesartan
Description: Candesartan Cilexetil (4-12 mg per day)
Study NCT01938300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Study NCT01938300 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Study NCT02419859 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PaQ® Insulin Delivery Device
Description: PaQ is a 3 day insulin delivery device which delivers U 100 rapid-acting insulin. Provides basal insulin at preset basal doses and bolus insulin (in 2 unit increments) with a push of a button.
Study NCT02419859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin, Asp(B28)-
Description: a fast-acting analog of human insulin
Study NCT00879554 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CVX-045
Description: Weekly, intravenous dose
Study NCT04290078 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kaia Back Pain Study App
Description: Kaia Back Pain is an integrated solution for self-management of low-back pain that digitizes multidisciplinary rehabilitation into a smartphone application.
Study NCT04290078 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants in the control arm will be provided with online links to educational materials about home exercises and pain management and asked to continue their usual care. On-line resources will include links to Web MD, the National Library of Medicine (Medline), and OnHealth
Study NCT04967716 — intervention group
Intervention type: OTHER
Intervention: basic information
Description: Demographic data registration, medical history inquiry, physical examination; electromyography, nerve conduction velocity examination; CMT nerve function score;
Study NCT04967716 — intervention group
Intervention type: OTHER
Intervention: venous blood test
Description: The specific method is as follows: 12ml of peripheral blood is drawn from the peripheral vein, and EDTA is used for anticoagulation. No fasting is required before blood draw, and there is no time limit. Part of the specimens submitted for inspection are sent to a qualified genetic testing company for examination, and the fees are charged in accordance with the corresponding charging standards set by the hospital. The remaining part of the sample will be stored or accumulated for a period of time, and the DNA will be extracted and stored in the sample library.
Study NCT00698178 — intervention group
Intervention type: OTHER
Intervention: Anthropometric measurements
Description: All patients undergo anthropometric measurements to record body weight, body height and waist circumference on the day of enrollment
Study NCT01094665 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI Targeted Focal Laser Thermal Therapy
Description: A 980nm wavelength diode laser will be fired for up to 30 minutes. Temperature probes will be inserted to ensure that the local temperature does not exceed 55 degrees Celsius for more than 5 minutes.
Study NCT01799993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amikacin Inhalation Solution (BAY41-6551)
Description: 400 mg of aerosolized amikacin every 12 hours for 10 days to be administered using the Pulmonary Drug Delivery System (PDDS Clinical)
Study NCT01799993 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aerosolized Placebo
Description: Aerosolized placebo every 12 hours for 10 days to be administered using the Pulmonary Drug Delivery System (PDDS Clinical)
Study NCT02823171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A: 400 mg Pacritinib P3CT
Description: 400-mg oral dose of pacritinib P3CT (reference) formulation capsules
Study NCT02823171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B: 400 mg of pacritinib FMI
Description: 400-mg oral dose of pacritinib FMI (test) formulation capsules
Study NCT01057888 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autodialer
Description: Autodialer telephone calls
Study NCT01057888 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Letters
Description: Mailed reminder letters
Study NCT02877745 — intervention group
Intervention type: OTHER
Intervention: Stratification, no intervention
Study NCT03401411 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Survey
Description: Survey of 15 fictional patient case scenarios to be assessed by participant using the standard prioritization or modified SCCMP to prioritize each patient scenario into one of a 5-point likert-scale categories for ICU admission. SCCMP scale categorized as 1-Critically ill to 4-Less likely to require ICU.
Study NCT03401411 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Algorithm-based Triage Tool
Description: Newly designed flowchart-based triage guide to prioritize each patient case scenario into one of the 5-point likert-scale categories, used in conjunction with SCCMP for ICU admission.
Study NCT03887468 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EvoCit
Description: hemodialysis using the combination of the Evodial dialyzer with a citrate enriched dialysate
Study NCT03887468 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EvoHep
Description: hemodialysis using the combination of the Evodial dialyzer with a conventional bicarbonate based dialysate and systemic anticoagulation using unfractionated heparin
Study NCT00295750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 160 mg SC (by injection under the skin) given every 28 days for 364 days.
Study NCT00295750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 80 mg SC (by injection under the skin) given every 28 days for 364 days.
Study NCT00295750 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprolide 7.5 mg
Description: Leuprolide (Lupron Depot) 7.5mg IM (in the muscle every 28 days starting at day 0.
Study NCT01204151 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: discrete-trial training
Study NCT02714439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proflavine
Description: Proflavine 0.01% applied to the cervix before high-resolution microendoscopy imaging procedure performed.
Study NCT02714439 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High-Resolution Microendoscopy (HRME)
Description: High-resolution microendoscopy imaging procedure performed after colposcopy exam. Standard colposcopy procedure will then continue. Entire HRME imaging procedure should add less than 10 minutes to the standard colposcopy exam.
Study NCT00450086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: 9 mg per day
Study NCT00450086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesalazine
Description: 3 g per day
Study NCT00450086 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0 g per day
Study NCT01840540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arterial infusion of autologous mesenchymal stem cells
Study NCT04114981 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Single Fraction Stereotactic Radiosurgery
Description: Undergo SSRS
Study NCT04114981 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fractionated Stereotactic Radiosurgery
Description: Undergo FSRS
Study NCT04114981 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04114981 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04114981 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies